Optimizing Post-Prostatectomy Radiotherapy: A Multi-Disciplinary Perspective
The joint ASTRO/AUA guideline for post-prostatectomy radiotherapy was published in 2013 and provides guidance when offering patients either adjuvant or salvage radiotherapy. While it was written to influence clinical management, multiple reports suggest that this has not occurred on a broad scale. Furthermore, new prospective data has added complexity to this clinical situation. Today, there are even more questions that regard the optimal timing of radiotherapy, treatment field design, and when to offer hormonal therapy. More contemporary issues regarding the availability of genomic signatures, and questions regarding the potential benefit of adjuvant chemotherapy. A contemporary update can therefore help update attendees who may be unfamiliar with many of the nuances introduced by these developments. A pair of academic radiation oncologists and a leading urologic oncologist will comprise the educational panel.
This activity was originally recorded at ASTRO’s 2017 Annual Meeting, September 24-27, 2017 in San Diego, CA.
This program is designed to meet the interest of radiation oncologists, radiation therapists, and radiation dosimetrists.
- Understand the quality of evidence that supports post-prostatectomy radiotherapy, hormonal therapy and chemotherapy.
- Become familiar with the role of genomic signatures to stratify patients for adjuvant therapies following prostatectomy.
- Drew Moghanaki, MD, MPH is employed by Virginia Commonwealth University and Hunter Holmes McGuire Veterans Medical Center and compensation/remuneration/funding from Varian Medical Systems and Veterans Affairs Cooperative Studies Program and holds leadership positions at ASTRO and Association of VA Hematology Oncology.
- Stephen J. Freedland, MD is employed by Cedars-Sinai and receives compensation/remuneration/funding from GenomeDx.
- Robert Den, MD is employed at Sidney Kimmel Medical College at Thomas Jefferson and receives compensation/remuneration/funding from Bayer and GenomeDx.
- Emmanuel S. Antonarakis, MD is employed at John Hopkins and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.